Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 370,000 ordinary shares of 25 pence each.
- Purchase Price: 1,364.796 pence per share.
- Treasury Shares Held: 112,083,000 shares following the transaction.
- Shares in Issue: 5,833,104,577 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 25, 2005. The company intends to hold the repurchased shares in Treasury.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 370,000 share repurchase based on the disclosed price of 1,364.796 pence.
- Confirm the updated total share count (5,833,104,577 in issue) against subsequent filings.
- Review the company's broader share buyback program status and remaining authorization limits.